Millennium Management’s Denali Therapeutics DNLI Stock Holding History

Millennium Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$288K	Buy	+15,000	New	+$298K	﹤0.01%	5024
2021 Q3	–	Sell	-52,300	Closed	-$4.1M	–	6867
2021 Q2	$4.1M	Sell	52,300 -12,700	-20%	-$786K	﹤0.01%	3024
2021 Q1	$3.71M	Buy	65,000 +15,000	+30%	+$1M	﹤0.01%	2910
2020 Q4	$4.19M	Buy	+50,000	New	+$3.02M	﹤0.01%	2614

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management's DNLI Position: Q1 2026 in Review

Millennium Management increased its Denali Therapeutics (DNLI) stake by 240% in Q1 2026, buying an estimated $17.7M and bringing the position to 1,257,950 shares worth $24.2M. The position accounts for 0.01% of the portfolio, ranked #1400.

Millennium Management first reported a position in DNLI in Q4 2017 and has held it in 26 quarters since. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

Millennium Management held 1,257,950 shares of Denali Therapeutics worth $24.2M as of Q1 2026.
Millennium Management bought 888,183 Denali Therapeutics shares in Q1 2026, an estimated $17.7M.
Denali Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1400 holding.
Millennium Management first reported a position in Denali Therapeutics in Q4 2017 and has held it in 26 quarters since.
268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.